Prime Medicine (PRME) Other Non-Current Assets (2021 - 2026)
Prime Medicine's (PRME) quarterly Other Non-Current Assets came in at $1.0 million in Q1 2026, down 92.89% YoY from $14.1 million in Q1 2025, and down 92.7% on a QoQ basis from $13.7 million in Q4 2025.
Prime Medicine (PRME) Other Non-Current Assets (2021 - 2026) Analysis & Trends
Prime Medicine (PRME) has 6 years of Other Non-Current Assets data on file, last reported at $1.0 million in Q1 2026.
- Quarterly Other Non-Current Assets fell 92.89% year-over-year to $1.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.0 million (down 92.89% YoY) and the FY2025 annual result came in at $13.7 million, down 2.64% from the prior year.
- Other Non-Current Assets retreated to $1.0 million in Q1 2026, from $13.7 million in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $14.1 million in Q3 2024 to a low of $1.0 million in Q1 2026.
- A 5-year average of $12.9 million and a median of $13.5 million in 2022 frame the typical range for Other Non-Current Assets.
- Annual changes were most pronounced in 2024 — Other Non-Current Assets grew 4.19% — and 2026, when it sank 92.89%.
- Tracing PRME's Other Non-Current Assets over 5 years: stood at $13.5 million in 2022, then changed by 0.0% to $13.5 million in 2023, then rose by 4.19% to $14.1 million in 2024, then fell by 2.64% to $13.7 million in 2025, then sank by 92.7% to $1.0 million in 2026.
- The last three Other Non-Current Assets figures came in at $1.0 million (Q1 2026), $13.7 million (Q4 2025), and $13.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 124.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 42.45 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 109.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 18,237.65 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 62.96 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 65.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 104.44 Mn |
| 10 | Prime Medicine | 558.48 Mn | 558.48 Mn | - | 13.69 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 13.69 Mn |
| Mar 31, 2026 | 1.00 Mn |
| Dec 31, 2025 | 13.69 Mn |
| Sep 30, 2025 | 13.69 Mn |
| Jun 30, 2025 | 13.69 Mn |
| Mar 31, 2025 | 14.06 Mn |
| Dec 31, 2024 | 14.06 Mn |
| Sep 30, 2024 | 14.06 Mn |
| Jun 30, 2024 | 13.50 Mn |
| Mar 31, 2024 | 13.50 Mn |
| Dec 31, 2023 | 13.50 Mn |
| Sep 30, 2023 | 13.50 Mn |
| Jun 30, 2023 | 13.50 Mn |
| Mar 31, 2023 | 13.50 Mn |
| Dec 31, 2022 | 13.50 Mn |
| Sep 30, 2022 | 13.50 Mn |
| Jun 30, 2022 | 13.50 Mn |
| Mar 31, 2022 | 13.13 Mn |
| Dec 31, 2021 | 13.13 Mn |